
Biomed Industries Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Agonist for Obesity at ENDO 2025
Biomed Industries, Inc. Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Receptor Agonist for the Treatment of Obesity at ENDO 2025 SAN JOSE, CA, UNITED STATES, July 17, 2025 /EINPresswire.com/ -- Biomed Industries, Inc. (Biomed …